LINC01594: A Protein Target for Brain and Cancer Treatments (G102724774)

Target Name: LINC01594

NCBI ID: G102724774

LINC01594

Other Name(s): TCONS_l2_00015893 | Long intergenic non-protein coding RNA 1594 | long intergenic non-protein coding RNA 1594

LINC01594: A Protein Target for Brain and Cancer Treatments

LINC01594 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the TCONS family, which includes proteins that are involved in the regulation of cell signaling pathways. LINC01594 is specifically known for its role in the regulation of the blood-brain barrier (BBB), which is a critical barrier that separates the brain from the rest of the body and is responsible for maintaining the integrity of the central nervous system (CNS).

The BBB is a selectively permeable barrier that helps to protect the brain from harmful substances and substances that are not meant to be present in the body. However, it is also known for being highly permeable, which means that it allows certain substances to enter the brain and contribute to the development of certain diseases, such as Alzheimer's disease.

LINC01594 is involved in the regulation of several different signaling pathways that are involved in the control of the BBB. For example, it has been shown to play a role in the regulation of the tight junction protein, which is responsible for maintaining the integrity of the BBB. Additionally, LINC01594 has been shown to be involved in the regulation of the neurotransmitter serotonin, which is involved in the regulation of mood, appetite, and other physiological processes.

In addition to its role in the regulation of the BBB, LINC01594 has also been shown to play a role in the development and progression of certain diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease, and has also been shown to be involved in the development of certain cancers.

Given its involvement in several different signaling pathways that are involved in the regulation of the BBB, LINC01594 is a promising drug target for the development of treatments for a variety of diseases. For example, it has been shown to be involved in the regulation of the blood-brain barrier in various diseases, including neurodegenerative diseases, which makes it a potential target for treatments that can help to overcome the limitations of the BBB.

In addition to its potential as a drug target, LINC01594 is also a valuable biomarker for the diagnosis and monitoring of certain diseases. For example, its expression has been shown to be involved in the development of certain neurological disorders, such as Alzheimer's disease, which makes it a potential biomarker for these disorders. Additionally, its expression has been shown to be involved in the development of certain cancers, which makes it a potential biomarker for these diseases as well.

Overall, LINC01594 is a protein that has the potential to be a drug target for the development of treatments for a variety of diseases. Its role in the regulation of the BBB and its involvement in the regulation of multiple signaling pathways make it a promising target for the development of treatments that can help to overcome the limitations of the BBB and treat a wide range of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1594

The "LINC01594 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01594 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets